


Darexaban

Chemical Properties

CAS No. :	365462-23-3
Formula:	C ₂₇ H ₃₀ N ₄ O ₄
Molecular Weight:	474.55
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Darexaban (Tanexaban, YM-150) is a direct inhibitor of Factor Xa. Darexaban and Darexaban glucuronide selectively and competitively inhibit FXA and inhibit prothrombin activity at the site of blood clot (thrombus) formation. This leads to a reduction in blood clot formation in a dose-dependent manner. Reducing clotting will reduce blockages in blood flow, which may reduce the risk of myocardial infarction, unstable angina, venous thrombosis, and ischemic stroke.
Targets(IC50)	Factor Xa, Serine Protease

Solubility Information

Solubility	DMSO: 245 mg/mL (516.28 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.54 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1073 mL	10.5363 mL	21.0726 mL
5 mM	0.4215 mL	2.1073 mL	4.2145 mL
10 mM	0.2107 mL	1.0536 mL	2.1073 mL
50 mM	0.0421 mL	0.2107 mL	0.4215 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Lip GY, Halperin JL, Petersen P, Rodgers GM, Pall D, Renfurm RW. A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2). *J Thromb Haemost.* 2015 Aug;13(8):1405-1doi: 10.1111/jth.1302Epub 2015 Jul 1
- Eriksson BI, Agnelli G, Gallus AS, Lassen MR, Prins MH, Renfurm RW, Kashiwa M, Turpie AG. Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). *Thromb Haemost.* 2014 Feb;111(2):213-2doi: 10.1160/TH13-04-0296. Epub 2013 Oct 17. PubMed PMID: 24136153.
- Kadokura T, Kashiwa M, Groenendaal D, Heeringa M, Mol R, Verheggen F, Garcia-Hernandez A, Onkels H. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects. *Biopharm Drug Dispos.* 2013 Nov;34(8):431-4doi: 10.1002/bdd.1858. Epub 2013 Sep 20. PubMed PMID: 23929659.
- Kadokura T, Groenendaal D, Heeringa M, Mol R, Verheggen F, Garcia-Hernandez A, Onkels H. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin. *Eur J Drug Metab Pharmacokinet.* 2014 Mar;39(1):1-9. doi: 10.1007/s13318-013-0141-Epub 2013 Jun 1PubMed PMID: 23754514.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481